BrightGene Bio-Medical Technology Co Ltd (BrightGene) is a biopharmaceutical company that manufactures, research and develop generic drugs. The company’s pipeline products include posaconazole, oseltamivir phosphate, orivancin, fidaxomycin, agatroban, fondaparinux, acarbose, iron supplements, trabectidine, pemetrexed disodium intermediate, eribulin mesylate, midotolin, everolimus and pimecrolimus, among others. Its veterinary drugs include seramectin, telavancin hydrochloride, emodes, doramectin and dalbavancin. The company develops products in the therapeutic areas of cardiology, oncology, antibacterial, antifungal and veterinary. BrightGene is headquartered in Suzhou, Jiangsu, China.
Headquarters
China
Address
Building C25-28, No.218 Xinghu Road, Sip, Suzhou, Jiangsu, 215123
Website
www.bright-gene.com
Telephone
86 512 62620988
No of Employees
1,128
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
688166 (SHA)
Revenue (2022)
$151.2M
-3.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-1.8%
(2022 vs 2021)
Market Cap*
$2.2B
Net Profit Margin (2022)
XYZ
1.6%
(2022 vs 2021)
* As of and is in US$
BrightGene Bio-Medical Technology Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anti-Infection Products | Bolining |
| Iron Supplements | Youchang |
| Antitumor Drugs | Borifunjin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In March, the company secured approval from FDA for Rezafungin. |
| 2022 | Regulatory Approval | In November, Borui Pharmaceuticals (Suzhou) Co., Ltd received the Pimecrolimus notice of rapproval of chemical raw drug marketing application issued by the State Drug Administration. |
| 2022 | Contracts/Agreements | In June, the company and the International Finance Corporation (IFC) of the World Bank Group signed the loan agreement for US$50 million. |
Competitor Comparison
| Key Parameters | BrightGene Bio-Medical Technology Co Ltd | China Pharma Holdings Inc | Ascletis Pharma Inc | Changzhou Sunlight Pharmaceutical Co Ltd | Crystal Pharmatech Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | United States of America |
| City | Suzhou | Haikou | Hangzhou | Changzhou | Cranbury |
| State/Province | Jiangsu | Hainan | Zhejiang | Jiangsu | New Jersey |
| No. of Employees | 1,128 | 234 | 243 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yuan Jiandong | General Manager; Chairman | Executive Board | 2017 | 53 |
| Ding Nan | Secretary | Senior Management | 2021 | 32 |
| Li Kai | Deputy General Manager | Senior Management | 2015 | 47 |
| Zou Yuanlai | Director - Financial | Senior Management | 2015 | 52 |
| Lu Dazhong | Director | Non Executive Board | 2017 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward